Phase I clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with malignant glioma.
Phase 1
- Conditions
- Malignant Glioma
- Registration Number
- JPRN-UMIN000003504
- Lead Sponsor
- Department of Cancer immunotherapy, Osaka University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
1. There is deep-seated active infection. 2,3 There are severe complications including malignant hypertention, cardiac failure, liver cirrhosis, severe DM, severe lung fiblosis, active interstitial pneumonitis.Patients who have complications that are considered inappropriate for the trial. 4. Dependent on total parenteral nutrition(TPN) 5. There are other malignancies. 6. There are hematopoietic stem cell disorders such as myelodisplastic syndorome(MDS) and myeloproliferative disorders (MPD). 7. Post allogeneic hematopoietic stem cell transplantation 8. Pregnant or lactating woman 9. There is severe psychiatric disorder. 10. Responsible doctors judged the patient inappropriate for the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety
- Secondary Outcome Measures
Name Time Method 1. Relapse-free survival time 2. Immune response to WT1